Regeneron : REGN

All Regeneron Articles

244 Articles

Jon C. Ogg | Nov 6, 2019 at 9:00 AM EST

Top Analyst Upgrades and Downgrades: Altice, CenturyLink, Cigna, Disney, Emerson, Foot Locker, Groupon, Lululemon, Nike, State Street and More

Wednesday's top analyst upgrades, downgrades and initiations included Altice USA, CenturyLink, Cigna, Emerson Electric, Foot Locker, Groupon, Lululemon Athletica, Nike,…

Lee Jackson | Aug 27, 2019 at 7:25 AM EDT

Top Baird Health Care and Biotech Picks Have Massive Upside Potential

One sector that has avoided much of the current trade and recession fear turmoil is health care, and especially the…

Jon C. Ogg | Aug 8, 2019 at 1:05 PM EDT

Oil & Gas, Apparel, Pharma Vying for S&P 500’s Worst Group of 2019

Of the 40 worst performers in the S&P 500 so far in 2019, 11 are tied to oil and gas,…

Jon C. Ogg | Jul 9, 2019 at 4:45 PM EDT

Many Top Pharma & Biotechs Rise as Drug Price Disclosure Thrown Out

President Trump lost ground with his efforts to force drug companies to list drug prices on TV ads, with the…

Jon C. Ogg | Jun 18, 2019 at 8:54 AM EDT

Top Analyst Upgrades and Downgrades: Array Bio, Bank of America, Oracle, Pinterest, RingCentral, Snap, SunPower, Twilio, Xilinx and More

Stocks were indicated to open higher on Tuesday after a small gain in the Dow and S&P 500 on Monday.…

Jon C. Ogg | Apr 24, 2019 at 12:55 PM EDT

Top Biotech Stocks and ETFs: A Sector in Trouble or a Huge Bargain

24/7 Wall St. has looked over some of the biotech sector's laggards, and we have also looked over the top…

Chris Lange | Apr 8, 2019 at 11:10 AM EDT

Should Alnylam Pharma Be Getting More Credit for Its Regeneron Deal?

Alnylam Pharma and Regeneron Pharma shares dipped on Monday despite announcing a collaboration to discover, develop and commercialize new RNA…

Chris Lange | Mar 11, 2019 at 4:14 PM EDT

Great News for Adolescents with Moderate to Severe Atopic Dermatitis

In an incredible move for adolescent patients 12 to 17 years of age, the U.S. Food and Drug Administration (FDA)…

Jon C. Ogg | Jan 4, 2019 at 10:20 AM EST

Top Analyst Upgrades and Downgrades: Bed Bath & Beyond, CBOE, eBay, Etsy, Intel, Netflix, Nokia, Snap, UTC, Vonage and More

The top analyst upgrades, downgrades and initiations seen on Friday included Bed Bath & Beyond, CBOE, eBay, Etsy, Intel, Netflix,…

Lee Jackson | Dec 14, 2018 at 9:14 AM EST

Top Analyst Upgrades and Downgrades: Activision, BioMarin, Ciena, Delta Air, GlaxoSmithKline, Procter & Gamble, Regeneron, Tesla and More

The top analyst upgrades, downgrades and initiations seen on Friday included Activision Blizzard, BioMarin Pharmaceuticals, Ciena, Delta Air Lines, GlaxoSmithKline,…

Jon C. Ogg | Nov 12, 2018 at 9:10 AM EST

Top Analyst Upgrades and Downgrades: Achaogen, Apple, Athenahealth, Crocs, Disney, Finisar, Jabil, Michael Kors, Occidental, Starbucks and More

The included Achaogen, Apple, Athenahealth, Crocs, Finisar, Jabil, Michael Kors, Occidental Petroleum, Starbucks and Walt Disney.

Chris Lange | Sep 27, 2018 at 4:08 PM EDT

Thursday’s Biggest Winners and Losers in the S&P 500

Thursday was a positive day for the broad U.S. markets. All three major indices recovered handily from Wednesday’s drop. Crude…

Lee Jackson | Sep 27, 2018 at 8:35 AM EDT

Merrill Lynch Loves Large Cap Biotech: 4 Top Stocks to Buy Now

Merrill Lynch recently highlighted sectors it considers a good opportunity now that are likely to outperform in the near term,…

Chris Lange | Aug 16, 2018 at 12:55 PM EDT

New Osteoarthritis Treatment Could Precipitate Another Blockbuster Drug

Teva and Regeneron both saw handy gains on Thursday after the companies posted positive topline results from their late-stage trial…

Chris Lange | Aug 15, 2018 at 9:35 AM EDT

What the FDA Has to Say About Regeneron’s Eylea

Regeneron Pharmaceuticals is facing some difficulty after it received an update from the FDA on Eylea (aflibercept) Injection in patients…

1 … 5 6 7 8 9 … 17

Regeneron : REGN

All Regeneron Articles

Top Analyst Upgrades and Downgrades: Altice, CenturyLink, Cigna, Disney, Emerson, Foot Locker, Groupon, Lululemon, Nike, State Street and More

Top Baird Health Care and Biotech Picks Have Massive Upside Potential

Oil & Gas, Apparel, Pharma Vying for S&P 500’s Worst Group of 2019

Many Top Pharma & Biotechs Rise as Drug Price Disclosure Thrown Out

Top Analyst Upgrades and Downgrades: Array Bio, Bank of America, Oracle, Pinterest, RingCentral, Snap, SunPower, Twilio, Xilinx and More

Top Biotech Stocks and ETFs: A Sector in Trouble or a Huge Bargain

Should Alnylam Pharma Be Getting More Credit for Its Regeneron Deal?

Great News for Adolescents with Moderate to Severe Atopic Dermatitis

Top Analyst Upgrades and Downgrades: Bed Bath & Beyond, CBOE, eBay, Etsy, Intel, Netflix, Nokia, Snap, UTC, Vonage and More

Top Analyst Upgrades and Downgrades: Activision, BioMarin, Ciena, Delta Air, GlaxoSmithKline, Procter & Gamble, Regeneron, Tesla and More

Top Analyst Upgrades and Downgrades: Achaogen, Apple, Athenahealth, Crocs, Disney, Finisar, Jabil, Michael Kors, Occidental, Starbucks and More

Thursday’s Biggest Winners and Losers in the S&P 500

Merrill Lynch Loves Large Cap Biotech: 4 Top Stocks to Buy Now

New Osteoarthritis Treatment Could Precipitate Another Blockbuster Drug

What the FDA Has to Say About Regeneron’s Eylea

XRP Price Prediction: 3 AI Models Predict Where XRP Will Trade by December 2026

QDVO’s 32% Return Masks a Hidden Risk for Income Investors

Half of America Still Feels Financially Exposed Despite 8% Jump in Security

Half of America Still Feels Financially Exposed Despite 8% Jump in Security

52% of Americans Are Building Wealth While Ignoring Their Greatest Risk

Kevin Warsh Would Be a Hawk at the Fed, but Productivity Boom Could Prevail

Ray Dalio: ‘We’re On the Brink’ of Major Problems Within 2 Years

Regeneron : REGN

All Regeneron Articles

Top Analyst Upgrades and Downgrades: Altice, CenturyLink, Cigna, Disney, Emerson, Foot Locker, Groupon, Lululemon, Nike, State Street and More

Top Baird Health Care and Biotech Picks Have Massive Upside Potential

Oil & Gas, Apparel, Pharma Vying for S&P 500’s Worst Group of 2019

Many Top Pharma & Biotechs Rise as Drug Price Disclosure Thrown Out

Top Analyst Upgrades and Downgrades: Array Bio, Bank of America, Oracle, Pinterest, RingCentral, Snap, SunPower, Twilio, Xilinx and More

Top Biotech Stocks and ETFs: A Sector in Trouble or a Huge Bargain

Should Alnylam Pharma Be Getting More Credit for Its Regeneron Deal?

Great News for Adolescents with Moderate to Severe Atopic Dermatitis

Top Analyst Upgrades and Downgrades: Bed Bath & Beyond, CBOE, eBay, Etsy, Intel, Netflix, Nokia, Snap, UTC, Vonage and More

Top Analyst Upgrades and Downgrades: Activision, BioMarin, Ciena, Delta Air, GlaxoSmithKline, Procter & Gamble, Regeneron, Tesla and More

Top Analyst Upgrades and Downgrades: Achaogen, Apple, Athenahealth, Crocs, Disney, Finisar, Jabil, Michael Kors, Occidental, Starbucks and More

Thursday’s Biggest Winners and Losers in the S&P 500

Merrill Lynch Loves Large Cap Biotech: 4 Top Stocks to Buy Now

New Osteoarthritis Treatment Could Precipitate Another Blockbuster Drug

What the FDA Has to Say About Regeneron’s Eylea

XRP Price Prediction: 3 AI Models Predict Where XRP Will Trade by December 2026

QDVO’s 32% Return Masks a Hidden Risk for Income Investors

Half of America Still Feels Financially Exposed Despite 8% Jump in Security

Featured Reads

Half of America Still Feels Financially Exposed Despite 8% Jump in Security

52% of Americans Are Building Wealth While Ignoring Their Greatest Risk